CAMBRIDGE, Mass., Sept. 16, 2011 /PRNewswire/ -- Pathfinder Cell Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that effective at the start of trading today, the ticker symbol for its common stock will change from SYMD to PFND. The new ticker symbol follows the recent change of the company's name and has been approved by the Financial Industry Regulatory Authority.
About Pathfinder Cell Therapy, Inc.
Pathfinder is developing a novel cell-based therapy with the potential to transform the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage. Leveraging its internal discovery of Pathfinder Cells ("PCs") and a proprietary means of isolating these cells from surrounding tissue, Pathfinder is pioneering a new field in regenerative medicine. PCs are a newly identified mammalian cell type present in very low quantities in a variety of different organs, including the kidney, liver, pancreas, lymph nodes, and other tissues.
Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the new tissue. The cells appear to be "immune privileged," and their effects are independent of the tissue source of PCs. PCs isolated from both rat and human tissue sources have shown efficacy in animal models of diabetes, cardiac ischemia and renal reperfusion injury.
For more information please visit: www.pathfindercelltherapy.com
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, risks related to regulatory approvals and the success of Pathfinder's ongoing and future studies, including the success of PCs, and uncertainties relating to the availability of capital to support Pathfinder's research, development and potential product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies. These and other risks and uncertainties are identified and described in more detail in the Company's filings with the Securities and Exchange Commission including the definitive proxy statement filed on July 26, 2011. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
For more information, please contact:
Chief Executive Officer
SOURCE Pathfinder Cell Therapy, Inc.